Literature DB >> 2960590

Control of cloned gene expression by promoter inversion in vivo: construction of improved vectors with a multiple cloning site and the Ptac promoter.

N Hasan1, W Szybalski.   

Abstract

We have constructed three gene-expression plasmids which contain (an) invertible promoter(s) and a multiple cloning site. We used either the plac promoter or the ptac-plac tandem promoters, the latter directing a more than fourfold increase in expression of the galK reporter gene in Escherichia coli host. All these plasmids were derived from the pNH7a expression plasmid of Podhajska et al. [Gene 40 (1985) 163-168]. Like pNH7a, these vectors have three novel properties: (i) in the 'OFF phase', the promoter is facing away from the gene to be expressed, (ii) the 'ON phase' is attained by the rapid and efficient inversion of the promoter mediated by the phage lambda Int product and the flanking attP and attB sites, which have a divergent orientation, and (iii) only a short heat pulse is required for the efficient inversion of the promoter and switching from the OFF to the ON phase. As for the pNH7 a vector, the present plasmids contain the nut-N transcriptional antitermination system, which permits efficient gene expression even if terminator(s) happen to be present between the promoter(s) and the expressed gene. The promoter inversion is rapid and over 95% efficient, as assayed by restriction analysis and galactokinase assay. Many genes could be conveniently cloned in the multiple cloning site, and then either kept totally silent or expressed in a rigidly controlled manner. Moreover, the pNH8, pNH16 and pNH18 plasmids, with already inverted promoters, could be used for expression of cloned genes, either in an unregulated manner or regulated by the lac repressor. They would be particularly useful for genes associated with terminators affecting their expression.

Entities:  

Mesh:

Year:  1987        PMID: 2960590     DOI: 10.1016/0378-1119(87)90167-3

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  9 in total

1.  An efficient recombination system for chromosome engineering in Escherichia coli.

Authors:  D Yu; H M Ellis; E C Lee; N A Jenkins; N G Copeland; D L Court
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  Structure and organization of the pel genes from Erwinia chrysanthemi EC16.

Authors:  S J Tamaki; S Gold; M Robeson; S Manulis; N T Keen
Journal:  J Bacteriol       Date:  1988-08       Impact factor: 3.490

3.  Tightly controlled two-stage expression vectors employing the Flp/FRT-mediated inversion of cloned genes.

Authors:  M Sektas; W Szybalski
Journal:  Mol Biotechnol       Date:  1998-02       Impact factor: 2.695

4.  A protective protein antigen of Rickettsia rickettsii has tandemly repeated, near-identical sequences.

Authors:  B E Anderson; G A McDonald; D C Jones; R L Regnery
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

Review 5.  Understanding the art of producing protein and nonprotein molecules in Escherichia coli.

Authors:  P Balbás
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

6.  The pilG gene product, required for Pseudomonas aeruginosa pilus production and twitching motility, is homologous to the enteric, single-domain response regulator CheY.

Authors:  A Darzins
Journal:  J Bacteriol       Date:  1993-09       Impact factor: 3.490

Review 7.  Strategies for achieving high-level expression of genes in Escherichia coli.

Authors:  S C Makrides
Journal:  Microbiol Rev       Date:  1996-09

8.  Protein-protein interaction: a genetic selection for compensating mutations at the barnase-barstar interface.

Authors:  M Jucovic; R W Hartley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

9.  s-cyclophilin is retained intracellularly via a unique COOH-terminal sequence and colocalizes with the calcium storage protein calreticulin.

Authors:  S Arber; K H Krause; P Caroni
Journal:  J Cell Biol       Date:  1992-01       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.